Securities Analyst Recommendations: NanoString Technologies, Inc. (NSTG), Bio-Techne Corporation (TECH)

NanoString Technologies, Inc. (NASDAQ:NSTG) tinted gains of +0.04% (+0.01 points) to US$22.31. The volume of 0.26 Million shares climbed down over an trading activity of 308.49 Million shares. EPS ratio determined by looking at last 12 month figures is -0.98. Over the same time span, the stock marked US$23.17 as its best level and the lowest price reached was US$5.87. The corporation has a market cap of US$691.16 Million.

NanoString Technologies, Inc. (NASDAQ:NSTG)’s earnings per share has been growing at a 67.8 percent rate over the past 5 year when average revenue increase was noted as 38 percent. The return on equity ratio or ROE stands at -206.8 percent while most common profitability ratio return on investment (ROI) was -0.8 percent. The company’s institutional ownership is monitored at 92.6 percent. The company’s net profit margin has achieved the current level of -58.1 percent and possesses 69 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 2 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 2 think it is Hold. Recently, analysts have updated the overall rating to 2. 1 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Bio-Techne Corporation (NASDAQ:TECH) is worth US$6.96 Billion and has recently risen 0.04% to US$183.8. The latest exchange of 0.38 Million shares is below its average trading activity of 244.63 Million shares. The day began at US$183.74 but the price moved to US$182.42 at one point during the trading and finally capitulating to a session high of US$185.68. The stock tapped a 52-week high of US$206.04 while the mean 12-month price target for the shares is US$187.63.

Currently, the stock carries a price to earnings ratio of 73.17, a price to book ratio of 6.33, and a price to sales ratio of 10.21. For the past 5 years, the company’s revenue has grown 15.7%, while the company’s earnings per share has grown -4.3%. With an institutional ownership near 96.3%, it carries an earnings per share ratio of 2.51.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 5 brokerage firms polled by Factset Research. At present, 4 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 0 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.89.